UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

LONDON, May 21 (Reuters) - Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.

Amryt, which already had a licence to sell lomitapide in Europe and countries including Russia, said it would raise $60 million in equity funding for the deal, which will create a group with combined proforma 2018 revenue of $136.5 million.

(Reporting by Paul Sandle, editing by Louise Heavens)